Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2016

View Archived Issues

Abzena and Baylor Scott & White Research Institute establish Denceptor Therapeutics joint venture

Savara closes acquisition of Serendex Pharmaceuticals

Merck & Co. patents describe BTK inhibitors

Universidad de Chile patents adeno-associated virus to treat cognitive disorders

Pierre Fabre Medicament discloses humanized antibodies for cancer therapy

Novira Therapeutics reports antiviral compounds

Targeting RANK pathway for breast cancer prevention in BRCA1-mutation carriers

MabVax starts enrollment in phase I trial of PET-imaging agent

Beta1-Integrin is a novel therapeutic target in pathological conditions of the muscle

T2 Biosystems and Bayer enter collaboration for hemostasis drug discovery and development

Auris Medical obtains fast track designation for Keyzilen

NEAT1 is a promising new target to modulate replication stress response and chemosensitivity

Phase II study of NurOwn for ALS meets primary endpoint

EVK-001 phase III clinical trial does not meet primary endpoint

ADCY9 gene polymorphisms affect dalcetrapib effects on cardiovascular outcomes

FDA approves Prezista expanded prescribing information

Nivolumab marketing applications accepted for filing

The EMA classifies AXAL as advanced therapy medicinal product

EMA accepts Ipsen's MAA for telotristat etiprate

Helix BioPharma and NRC enter agreement in principle to collaborate on immuno-oncology initiatives

Vernalis and Servier achieve a milestone in oncology collaboration

Merck & Co. begins enrolling participants in phase I trial of MK-1966 in combination with SD-101

FDA clears Bexion Pharmaceuticals' phase I application for BXQ-350

Avedro receives additional indication for Photrexa Viscous, Photrexa and the KXL System

FDA approves Berinert as the first and only pediatric treatment for hereditary angioedema

Soligenix to present positive preliminary results of a heat stable Ebola vaccine formulation